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A large body of evidence revealed that compared with 
children and adolescents in the general population, those 
with type 1 diabetes mellitus (T1DM) are at excessive 
risk of diabetes related complications (1,2). Presence and 
long-term diabetes complications are known to increase 
cardiovascular (CV) morbidity and mortality in population 
with T1DM in which 26.1% of all deaths are associated 
with diabetes complications (3).
Multiple factors and diseases such as the thickness of 
glomerular and tubular basement membrane, increased 
glomerular filtration rate (GFR), dyslipidemia, increased 
arterial stiffness and carotid intima-media thickness (CIMT) 
are important predictors for renal and cardiovascular 
diseases (CVD) (4,5). Progression in albuminuria known as 
“diabetic nephropathy” is a frequent complication related 
to T1DM which is more prevalent among patients with 
a longer duration of diabetes and poor glycemic control. 
Microalbuminuria defined as urine albumin excretion 
of 30–299 mg/day or an albumin to creatinine ratio of 
30–299 mg/g creatinine is the earliest clinical sign of 
childhood diabetic nephropathy occurring during the first 
years after the onset of T1DM. Persistent microalbuminuria 
is highly predictive of CVD risk later in life. Overall 
prevalence rate of microalbuminuria is roughly 30% in 
patients with 7 years T1DM duration (6). Microalbuminuria 
can progress to macroalbuminuria which is defined as urine 
albumin excretion ≥300 mg/day or albumin to creatinine 
ratio ≥300 mg/g creatinine, and indicates the onset of 
overt diabetic nephropathy (6,7). Patients with T1DM and 
diabetic nephropathy are at higher risk of CVD compared 
with those without nephropathy. It is also shown that 
diabetic nephropathy is the leading cause of end-stage renal 
disease (ESRD) in developed countries (8). Undertreated 
patients with microalbuminuria may further progress to 
overt proteinuria and ESRD. Interventions aiming at 
improving glycemic control, blood pressure and lipid levels 
significantly influence the risk of diabetic nephropathy (8).
It is likely that the pathogenesis of diabetic vascular 
complications involves metabolic and functional factors 
which are triggered by genetic, biological and environmental 
factors. Gender, race/ethnicity, family history of CVD, high 
blood pressure (both systolic and diastolic blood pressure), 
high lipid levels, diet, lifestyle factors e.g., smoking and 
diabetes duration are among potential risk factors associated 
with the progress in diabetic complications in adolescents 
with T1DM (9). Puberty has also been shown to increase 
the risk of albuminuria which leads to the progress in CVD 
and risk factors; microalbuminuria is often diagnosed during 
puberty (10). Moreover, poor glycemic control due to 
decreased insulin sensitivity is common among adolescents 
with T1DM and is linked to the development of vascular 
complications (11). The effect of intensive insulin therapy 
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and improved glycemic control on reducing the risk of 
vascular complications has been established (12).
Angiotensin converting enzyme inhibitors (ACEIs) and 
statins are commonly used in adults with diabetes, but they 
have not been fully evaluated in younger patients. Despite 
the recommendation from available guidelines (13,14) 
to start medication treatment in T1DM children and 
adolescents with CVD risk factors, use of CV medication 
is low in this population (1,2). In a large population-based 
study, in children with T1DM compared with a matched 
diabetes-free reference cohort, we showed that substantial 
number of T1DM children with hypertension (50%) and 
hypercholesterolemia (53%) were undertreated for a period 
of 2–5 years during the 20-year follow-up (2).
Despite higher rates of diabetes related complications 
in children and adolescents with T1DM, data on long-
term prophylactic CV medication use in this population 
is limited. Recently, Marcovecchio and colleagues from 
the University of Cambridge presented the results of 
the AdDIT (Adolescent Type 1 Diabetes Cardio-Renal 
Intervention Trial) (15). This study is the first double-blind, 
randomized, placebo-controlled trial to test the hypothesis 
that T1DM adolescents with albuminuria might benefit 
from ACEIs and statins therapy. This trial is a multicenter 
study in 32 centers in the United Kingdom, Canada, and 
Australia that evaluated the effects of ACEIs and statins on 
CVD and CVD risk factors in T1DM adolescents aged 10 
and 16 years who were at high risk of albuminuria. After 
screening of 4,407 adolescents with T1DM, 443 high risk 
individuals (with increased albumin excretion defined as 
the upper third of the albumin-to creatinine ratios) were 
included in this trial; dropout rate was 20%. The inclusion 
of T1DM was based on diabetes diagnosis at least 1 year 
before the trial initiation. Patients were randomly assigned 
to receive placebo, an ACEI (quinapril 5–10 mg per day), a 
statin (atorvastatin 10 mg), or a combination of the ACEI 
or the statin. Change in albumin excretion was the primary 
outcome assessed based on the albumin-to-creatinine ratio 
every 6 months. Several secondary outcomes including 
microalbuminuria, progression of retinopathy, changes in 
the GFR, lipid levels, and other CVD risk markers e.g., 
CIMT were assessed. The median follow-up was 2.6 years.
The results of this study revealed that albumin excretion 
(primary outcome) in this population was not affected by the 
three different medications regimens (quinapril, atorvastatin, 
or the combination of the two). However, quinapril was 
shown to reduce the incidence rate of microalbuminuria 
as a secondary outcome (adjusted HR: 0.57; 95% CI: 
0.34–0.94, P=0.03) when compared to placebo. Though the 
results shown were not considered statistically significant 
(the threshold for secondary outcomes was set at P<0.01), 
they might be clinically important for adolescents who are 
at high risk of albuminuria. Progression in albuminuria or 
diabetic nephropathy confers a higher risk of CVD and 
CVD risk factors according to the results of the Diabetes 
Control and Complications Trial (DCCT) and the 
Epidemiology of Diabetes Interventions and Complications 
(EDIC) study (16). Moreover, the Finnish Diabetic 
Nephropathy (FinnDiane) Study showed a reduction 
in the risk of CVD events due to the nephropathy 
regression (17). Atorvastatin therapy, as expected, resulted 
in significant reductions in lipid traits consistent with 
previous trial. Recently, a small randomized, double blind, 
placebo-controlled pilot trial that included 42 adolescents 
with T1DM and elevated low-density lipoprotein (LDL) 
cholesterol showed a decreased lipid levels by atorvastatin 
therapy. Atorvastatin was safe and well tolerated in this 
study (18). However, very few studies investigated the effect 
of statins on CVD outcomes. The Pediatric Atorvastatin in 
Diabetes Trial (PADIT) which is a pilot study to assess the 
effect of 12 weeks treatment with atorvastatin versus placebo 
on arterial stiffness and endothelial function in children 
with T1DM showed no progress on CVD outcomes (19). 
In the AdDIT trial, both quinapril and atorvastatin had no 
significant effects on CIMT or on other CVD markers, 
in contrast to the findings from previous studies involving 
adults. Different results might rely on individuals’ age, 
duration of medication treatment, medication adherence, 
sample size and types/dosages of medications used. 
Concerning the safety of pharmacotherapy in this trial, a 
few patients had serious adverse drug reactions to quinapril 
consisting of decreased estimated GFR (2/222 patients), 
postural hypotension (1/222 patients), and increased alanine 
aminotransferase level (1/222 patients). No serious side 
effects were shown with the atorvastatin therapy; only 
one patient reported any muscle symptoms during the 
follow-up.
The AdDIT trial had certain limitations that should 
be acknowledged. Misclassification of albuminuria is one 
of the important limitations in this trial. The prevalence 
rate of proteinuria, mainly albuminuria in children and 
adolescents, is high, ranging from 75% to 95% which is 
often due to transient and orthostatic proteinuria associated 
with exercise, fever, cold, and/or stress (20). The presence 
of persistent albuminuria requires repeated measurements 
of urine protein excretion in the absence of such conditions 
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causing transient and orthostatic proteinuria. Additionally, 
it is likely to under/overestimate the albumin excretion 
(albumin to creatinine ratio) in different populations as 
this trial applied a single threshold of 31 mg/g in males 
and 35.4 mg/g in females; age, body size, gender and 
race have been shown to alter the albumin excretion (21). 
Besides, the diversity of centers and different instruments 
for measuring CIMT might influence the results of this 
study. As reported, CIMT was measured at different 
specialized vascular centers, however, all biochemical 
measurements including urine albumin were performed 
in a central laboratory (WellChild Laboratory, London) 
which strengthens the findings of this study. Selection 
bias might have influenced the results of the trial because 
patients that participated in the trial might have been more 
likely to be compliant with therapy compared with patients 
that did not want to participate. Relatively short duration 
of medication treatment (2–4 years) is another important 
limitation in this study. A delayed “legacy effect” of early 
medication treatment with ACEIs and statins might explain 
the negative results of this study. Moreover, medication 
adherence rate might influence the presented results (22); 
suboptimal adherence contributes to less effective 
medications. Generally, adolescents with T1DM have 
poorer medication adherence compared with other pediatric 
population (23); however, medication adherence in the 
AdDIT trial, measured by counting the returned unused 
pills, was 75% consistent with previous questionnaire 
based survey (24), and significantly higher than the rates in 
previous adolescent cohorts (22).
Given the high risk of subclinical CVD events and CVD 
risk factors among children and adolescents with T1DM and 
because CVD is the major cause of death (33.6%) after the 
age of 30 years in patients with childhood-onset T1DM (25), 
targeting CVD risk factors to reduce long-term vascular 
complications in children with T1DM is critical, once 
diabetes is diagnosed. As vascular complications related 
to diabetes are often asymptomatic in early stages, annual 
repeated screening initiated during early adolescence is 
also strongly recommended. Moreover, studies to clarify 
markers/biomarkers associated with diabetes complications 
and implementing early preventive strategies to reduce the 
burden of complications among this population is of upmost 
importance. How modification of these factors affects the 
progression of CVD is also warranted.
The AdDIT trial highlights need for conducting more 
longitudinal studies aiming at whether children and 
adolescents with T1DM and at high risk of CVD and CVD 
risk factors should be treated. According to the current US 
and European guidelines (13,14), ACEIs and statins are 
among the most effective and safe pharmacotherapies to 
reduce CVD and risk factors and they are recommended 
for use in adolescents with diabetes and established 
complications such as hypertension, persistent albuminuria 
and hyperlipidemia. However, the optimal approach to 
prevent long term CVD in T1DM children and adolescents 
remains controversial. Since the real effect of these 
medications might be expected in adulthood, drawing firm 
conclusions about efficacy and safety of prevention therapy 
in this population needs longer treatment follow-up.
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